The Use of Pentoxifylline and Vitamin E in the Treatment of Late Radiation Related Injuries
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00188552
Recruitment Status :
(May 2007: No annual renewal)
Patients with radiation induced injuries experience significant pain and negative effects on quality of life. Currently, no standard therapy for these patients exists, with some patients treated symptomatically, and others treated with hyperbaric oxygen or pentoxifylline/Vitamin E. This study will examine prospectively the safety and efficacy of using a regimen of pentoxifylline and vitamin E in patients with late radiation induced injuries.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Prior treatment with radiation therapy to the affected area - completed at least 3 months prior to study entry
Pain in irradiated volume after 3 months (not attributable to acute inflammation)
ECOG performance status must be 0, 1 or 2
Life expectancy is greater than 6 months
Age 18 to 75 years; informed consent
Patient is still responding to other therapies for soft tissue injury
Active malignant disease
Any medical illness or condition judged likely by the local investigator to preclude safe administration of protocol treatment, including but not limited to, acute myocardial infarction, severe coronary artery disease, active internal bleeding or a history of hemorrhagic diathesis, peptic ulcer, impaired kidney or liver function
Pregnant or lactating women
No contraindication to treatment with pentoxifylline. (i.e. previously exhibited intolerance to pentoxifylline or other xanthines such as caffeine, theophylline or theobromine, recent cerebral and/or retinal hemorrhage)
Concurrent treatment with warfarin or other anticoagulant, or with erythromycin
Concurrent treatment with other experimental agents or other treatment for fibrosis
Patients treated with radiotherapy for breast cancer 3 months to 3 years prior to study entry
Blood pressure < 90/60 mm Hg or orthostatic hypotension